Skip to main content

Deschatelets Pascal's Form 4 filing

Apellis Pharmaceuticals, Inc. (APLS) · filed Jun 9, 2022

Accession no.
0001127602-22-017181
Filed
Jun 9, 2022
Trade date
Jun 8, 2022
Filing delay
1 day
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market sales total $529.1K. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Deschatelets PascalCIK 0001657720Officer (Chief Scientific Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jun 8, 2022Common StockMOption exerciseAcquired+12,000$2.67+$32,040903,775Direct
Jun 8, 2022Common StockSSaleDisposed−12,000$44.09−$529,080891,775Direct
Jun 8, 2022Common StockMOption exerciseAcquired+6,500$2.67+$17,355898,275Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jun 8, 2022Common StockMOption exerciseDisposed−12,000$0.00$0352,999Direct
Jun 8, 2022Common StockMOption exerciseDisposed−6,500$0.00$0346,499Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)